Cancer patients monitored for 5 years after experimental treatment
NCT ID NCT06887348
Summary
This study is monitoring patients for five years after they received an experimental cancer immunotherapy from Replimune. The goal is to check for any delayed side effects or safety issues that might appear long after treatment. About 50 patients with cancers like melanoma or liver cancer who received the therapy in a previous study will be contacted regularly by phone to track their health.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tasman Oncology Research
RECRUITINGSouthport, Queensland, 4215, Australia
Contact
-
UC San Diego Moores Cancer Center
RECRUITINGLa Jolla, California, 92093-0698, United States
Contact
Conditions
Explore the condition pages connected to this study.